Corlanor

(Ivabradine)

ApprovedSmall molecule

Ivabradine is used to treat heart failure and reduce the need for hospitalization in patients with chronic heart failure. It works by slowing down the heart rate to help the heart work more efficiently.[2] Corlanor is currently approved and in use across 34 indications[4].[1]

Corlanor is one of 591 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

590

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Coronary Artery DiseaseApproved

Cardiovascular DiseaseActive, not recruiting

Migraine Without AuraActive, not recruiting

MyocarditisActive, not recruiting

IschemiaActive, not recruiting

BradycardiaActive, not recruiting

Orthostatic IntoleranceApproved

LymphomaApproved

Acute Coronary SyndromeActive, not recruiting

Acute MyocarditisActive, not recruiting

Coronary Artery DiseaseApproved

Approved

Cardiovascular DiseaseApproved

Active, not recruiting

Migraine Without AuraPreclinical

Active, not recruiting

MyocarditisPreclinical

Active, not recruiting

IschemiaApproved

Active, not recruiting

BradycardiaPreclinical

Active, not recruiting

Orthostatic IntoleranceApproved

Approved

LymphomaApproved

Approved

Acute Coronary SyndromeApproved

Active, not recruiting

Acute MyocarditisPreclinical

Active, not recruiting

Showing 10 of 33 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Corlanor

Amgen

Approved

1 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Nexavar

Bayer

Preclinical

1 5

Singulair

AstraZeneca

Preclinical

1 6

Calciferol

Alnylam Pharmaceuticals

Preclinical

—7

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 8

Nitrostat

VViatris Specialty LLC

Preclinical

1 9

Nadroparin

GSK

Preclinical

1 10

Statins

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Failure14 trials

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Completed· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 3·NCT02441218·6,505 enrolled

Iatrogenic Chronotropic Incompetence and Exercise Tolerance in Heart Failure

Unknown status·TThe Leeds Teaching Hospitals NHS Trust·N/A·NCT02086422

Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes

Withdrawn·UUniversity of Maryland, Baltimore·Phase 4·NCT03631654

Show 11 more trials

A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.

Completed· Amgen logo

Amgen·Phase 4·NCT03456856·30 enrolled

Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT01373619·150 enrolled

Early Use of Ivabradine in Heart Failure

Unknown status·—·N/A·NCT03701880·50 enrolled

Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure

Completed·—·Phase 4·NCT01699776·22 enrolled

Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction

Unknown status·KKocaeli University·Phase 4·NCT02046044·60 enrolled

Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients

Completed·GGetz Pharma··NCT03710057·50 enrolled

Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

Completed·—·Phase 4·NCT02827500·104 enrolled

The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)

Completed·UUniversity of Oxford·N/A·NCT02354573·121 enrolled

Control of Sinus Node Tachycardia as an Additional Therapy in Patients With Decompensated Heart Failure

Unknown status·UUniversity of Sao Paulo·Phase 1/2·NCT02236247·50 enrolled

Heart Rate Reduction in Heart Failure

Completed·IIRCCS San Raffaele·Phase 3·NCT01178528·121 enrolled

Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker

Unknown status·RRajaie Cardiovascular Medical and Research Center·N/A·NCT03830957·200 enrolled

Coronary Artery Disease5 trials

The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction

Completed· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 3·NCT00143507·10,917 enrolled

Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease

Completed·—·Phase 4·NCT02681978·70 enrolled

Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease

Completed·IInsel Gruppe AG, University Hospital Bern·N/A·NCT01039389·43 enrolled

Show 2 more trials

Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease

Enrolling by invitation·GGødstrup Hospital·Phase 2/3·NCT07268170·350 enrolled

Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure

Completed· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 3·NCT02446990·19,102 enrolled

Heart5 trials

Ivabradine in Hemodialysed Patients With Increased Heart Rate

Unknown status·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT01364077·100 enrolled

Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals

Terminated·BBayside Health·Phase 4·NCT00825123·2 enrolled

The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals

Withdrawn·BBayside Health·Phase 4·NCT01029223·42 enrolled

Show 2 more trials

Heart Rate Controller in Computed Tomography Coronary Angiography

Unknown status·MMahidol University·Phase 4·NCT05261464·246 enrolled

Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)

Completed·UUniversity Hospital, Rouen·Phase 3·NCT02584439·20 enrolled

Tachycardia4 trials

Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome

Completed·UUniversity of California, San Diego·Phase 3·NCT03182725·37 enrolled

The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 2·NCT01761825·20 enrolled

Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial.

Recruiting·—·N/A·NCT06505668·40 enrolled

Show 1 more trial

Ivabradine Versus Beta-blockers in the Treatment of Inappropriate Sinus Tachycardia

Completed·PPoliclinico Casilino ASL RMB·Phase 3·NCT01657136·20 enrolled

Atrial Fibrillation3 trials

IvaBRAdine blocK of Funny Current for Heart Rate Control in permanEnt Atrial Fibrillation. (BRAKE-AF Study).

Completed·AAdolfo Fontenla·Phase 3·NCT03718273·68 enrolled

Ivabradine for Rate Control in Permanent Atrial Fibrillation

Completed·YYale University·Phase 1·NCT03987204·4 enrolled

Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction

Unknown status·CChun-Yao Huang·Phase 3·NCT04308031·100 enrolled

38 more indications

Congestive Heart Failure2 trials

Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure

Completed· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 2·NCT00202579·12 enrolled

Ivabradine in Patients With Congestive Heart Failure

Completed·—·Phase 4·NCT04448899·60 enrolled

Cardiotoxicity2 trials

Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

Unknown status·UUniversity of Sao Paulo·N/A·NCT03650205·160 enrolled

Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

Unknown status·VVilnius University·Phase 3·NCT04030546·128 enrolled

Sepsis2 trials

Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis

Unknown status·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 4·NCT05882708·172 enrolled

Reducing Elevated Heart Rate in Patients With Severe Sepsis by Ivabradine

Unknown status·PPeking Union Medical College Hospital·N/A·NCT03367026·70 enrolled

Function2 trials

Ivabradine and Post-revascularisation Microcirculatory Dysfunction

Withdrawn·LLiverpool Heart and Chest Hospital NHS Foundation Trust·Phase 4·NCT02507050

Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine

Unknown status·MMartin-Luther-Universität Halle-Wittenberg·Phase 2·NCT01186783·70 enrolled

Cardiac2 trials

Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy

Unknown status·MMedical University of Warsaw·Phase 4·NCT02166060·60 enrolled

Heart Rate Reducing Therapy in Cardiac CT Using Ivabradine and Bisoprolol

Completed·MMedical University of Graz··NCT02764970·112 enrolled

Type 2 Diabetes1 trial

IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease

Withdrawn·NNanjing First Hospital, Nanjing Medical University·Phase 3·NCT03105219

Quality of Life1 trial

Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm

Completed·—·Phase 4·NCT06371222·42 enrolled

Transplant Recipient1 trial

An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients

Withdrawn· Amgen logo

Amgen·Phase 3·NCT03619187

Pacemaker1 trial

The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.

Completed·UUniversity of Leeds·N/A·NCT02247245·40 enrolled

MPA1 trial

Comparison Between Atenolol,Propnalol and Ivabradine

Completed·MMenoufia University·N/A·NCT06670690·120 enrolled

Myocardial Ischemia1 trial

Effects of Ivabradine on Residual Myocardial Ischemia After PCI

Completed·AAzienda Policlinico Umberto I·Phase 4·NCT03866395·28 enrolled

Radiation Therapy1 trial

Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

Terminated·—·Phase 2·NCT03137537·23 enrolled

Septic Shock1 trial

Ivabradine for Heart Rate Control In Septic Shock

Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04031573·429 enrolled

Safety and Efficacy1 trial

To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina

Unknown status·XXintong Pharmacy Company·Phase 2·NCT02623569·336 enrolled

Chronic Coronary Syndrome1 trial

the Role of Ivabradine in Causing AF in Patients With Chronic Coronary Syndrome

Unknown status·—··NCT05168189·180 enrolled

COVID-191 trial

Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort

Unknown status·UUniformed Services University of the Health Sciences·Phase 4·NCT05481177·250 enrolled

Heart Disease1 trial

Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease

Unknown status·UUniversity Hospital, Saarland·Phase 4·NCT01768585·50 enrolled

Cardiogenic Shock1 trial

Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine

Unknown status·LLoyola University·Phase 4·NCT03387605·40 enrolled

Liver Disease1 trial

Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02294292·189 enrolled

Hypotensive Anesthesia1 trial

Efficacy of Ivabradine Versus Propranolol Premedication During Hypotensive Anesthesia in Endoscopic Sinus Surgery

Unknown status·—·N/A·NCT04208594·50 enrolled

Effectiveness1 trial

Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit

Terminated·PPhillip Levy·Phase 4·NCT03168529·19 enrolled

Interaction1 trial

Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers

Completed·—·Phase 3·NCT03485482·18 enrolled

Acute Coronary Syndrome1 trial

Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome

Completed·HHospital Universitario de Canarias·Phase 4·NCT00815100·27 enrolled

Diastolic Heart Failure1 trial

If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure

Withdrawn·SSt Vincent's University Hospital, Ireland·Phase 2·NCT00757055

Migraine Without Aura1 trial

Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)

Completed·DDanish Headache Center·N/A·NCT04853797·37 enrolled

Efficacy1 trial

Efficacy of Oral Ivabradine in Patients Presenting With NSTEMI

Completed·—·Phase 2/3·NCT04285736·100 enrolled

Cardiac Surgery1 trial

PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery

Completed·UUniversity Hospital, Geneva·Phase 4·NCT04436016·78 enrolled

Acute Myocarditis1 trial

Value of Heart Rate Lowering Therapy in Acute Myocarditis

Recruiting·—··NCT06312891·150 enrolled

STEMI1 trial

Clinical Study of CMR to Evaluate the Effect of Ivabradine on the Improvement of Left Ventricular Remodeling in STEMI Patients After Primary PCI

Unknown status·QQian geng·Phase 4·NCT05348057·240 enrolled

Heart Transplantation1 trial

Effect of Ivabradine on Exercise Capacity After Heart Transplantation

Unknown status·FFinn Gustafsson·Phase 4·NCT03405831·35 enrolled

Angina Pectoris1 trial

Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris

Completed· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 3·NCT00202566·750 enrolled

Ischemia1 trial

Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol

Unknown status·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT01425164·220 enrolled

Tolerance1 trial

Effect of Ivabradine on Heart Rate & Effort Tolerance in Mitral Stenosis in Sinus Rhythm

Completed·GGovind Ballabh Pant Hospital·Phase 3·NCT01022463·50 enrolled

Injury1 trial

Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)

Active, not recruiting·JJagiellonian University·Phase 3·NCT05279651·2,146 enrolled

Efficacy and Safety1 trial

Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock

Unknown status·HHospital Universitario Ramon y Cajal·Phase 4·NCT03437369·22 enrolled

Airway Disease1 trial

HR-lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease

Completed·MMedical University of Lodz·Phase 4·NCT01365286·40 enrolled

Hypothalamic Obesity1 trial

SETMELANOTIDE-RM: Setmelanotide in Rare Obesity

Active, not recruiting· Rhythm Pharmaceuticals logo

Rhythm Pharmaceuticals·Phase 3·NCT04580342·155 enrolled

Unspecified2 trials

RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)

Completed·KKanecia Obie Zimmerman·Phase 2·NCT06305806·181 enrolled

Pulse Reduction On Beta-blocker and Ivabradine Therapy

Completed·UUniversity of Colorado, Denver·Phase 4·NCT02973594·28 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 15, 2015

CORLANOR

NDA NDA206143

Apr 22, 2019

CORLANOR

NDA NDA209964

Sources

References

[1]
ClinicalTrials.gov — 75 trial records for Ivabradine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Corlanor drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ivabradine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ivabradine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA209964). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Corlanor. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Potassium/sodium Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 4 Blocker[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Amgen

Patent Landscape[6]

Patent Cliff

Aug 22, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7361649Feb 22, 2026

7879842Feb 22, 2026

7361650Feb 22, 2026

7361650*PEDAug 22, 2026

7879842*PEDAug 22, 2026

3 more patents

7361649*PEDAug 22, 2026

7867996Dec 12, 2026

7867996*PEDJun 12, 2027

Corlanor

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Heart Failure14 trials

Coronary Artery Disease5 trials

Heart5 trials

Tachycardia4 trials

Atrial Fibrillation3 trials

Congestive Heart Failure2 trials

Cardiotoxicity2 trials

Sepsis2 trials

Function2 trials

Cardiac2 trials

Type 2 Diabetes1 trial

Quality of Life1 trial

Transplant Recipient1 trial

Pacemaker1 trial

MPA1 trial

Myocardial Ischemia1 trial

Radiation Therapy1 trial

Septic Shock1 trial

Safety and Efficacy1 trial

Chronic Coronary Syndrome1 trial

COVID-191 trial

Heart Disease1 trial

Cardiogenic Shock1 trial

Liver Disease1 trial

Hypotensive Anesthesia1 trial

Effectiveness1 trial

Interaction1 trial

Acute Coronary Syndrome1 trial

Diastolic Heart Failure1 trial

Migraine Without Aura1 trial

Efficacy1 trial

Cardiac Surgery1 trial

Acute Myocarditis1 trial

STEMI1 trial

Heart Transplantation1 trial

Angina Pectoris1 trial

Ischemia1 trial

Tolerance1 trial

Injury1 trial

Efficacy and Safety1 trial

Airway Disease1 trial

Hypothalamic Obesity1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News